1. Introduction {#sec1-ijms-17-01715}
===============

Hepatitis B (HepB) is an infection with the hepatitis B virus (HBV), which attacks the liver and can cause both acute and chronic disease. The World Health Organization (WHO) estimates that 240 million persons are chronically infected with HBV and that more than 780,000 people die every year due to complications of HepB, including cirrhosis and liver cancer \[[@B1-ijms-17-01715]\]. The point that needs the most attention is the high rates of chronic infection found in the sub-Saharan Africa and East Asia, where between 5% and 10% of the adult population is infected, as well as in the Amazon and the southern parts of eastern and central Europe. Otherwise, less than 1% of the population in Western Europe and North America is chronically infected \[[@B1-ijms-17-01715]\].

HBV is a hepatotropic DNA virus that replicates by reverse transcription. The human HBV is a small circular DNA molecule of 3.2 kb \[[@B2-ijms-17-01715]\]. Its genome consists of four partially overlapping open reading frames (ORFs), namely the envelope gene (*pre*-*surface*/*surface* (*pre*-*S*/*S*)), the core gene (*pre*-*core*/*core* (*pre*-*C*/*C*)), the polymerase gene (*pol*) and the transactivating protein X (*X*). The ORF *pre*-*S*/*S* encodes pre-S1, pre-S2 and surface (S) proteins that form the surface antigen (HBsAg), and HBsAg protein is the main antigen to elicit virus-neutralizing and protective antibodies by the immune system \[[@B3-ijms-17-01715],[@B4-ijms-17-01715]\]. Understanding the HBV genome and structure is an essential prerequisite for preventive or therapeutic vaccination against HepB.

2. Approach for HBV Vaccine {#sec2-ijms-17-01715}
===========================

A vaccine against HepB has been available since 1982. This first licensed anti-HBV vaccine containing subviral particles of HBV purified from the inactivated serum of carriers revealed very high efficacy \[[@B5-ijms-17-01715]\], and a subsequent subunit vaccine made using the small surface antigen (S-HBsAg) was developed in the early 1980s \[[@B6-ijms-17-01715]\]. The yeast system for the recombinant antigen was to ensure safety and low cost. Yeast-derived S-HBsAg assembled into virus-like particles (VLPs) were as immunogenic as natural subviral particles, and highly effective vaccines containing S-HBsAg have been widely used as prophylactic vaccines against HBV infection \[[@B7-ijms-17-01715]\]. However, some groups of vaccines do not develop protective immunity against the virus and immunosenescence frequently occurs in adults \[[@B8-ijms-17-01715]\]. Additionally, high cost limit and the necessity of accompanying infrastructure for the cold chain distribution and intravenous administration still constituted a barrier to vaccination approaches in developing countries. In order to successfully solve these problems, many research projects have been undertaken to develop more efficacious, easily administrated, and thermostable vaccines.

A new recombinant HBV vaccine containing the *pre*-*S*/*S* has greater immunogenic potential than the conventional S antigen-based vaccines in terms of antibody induction and cellular immune response. Middle (pre-S2 + S, M-HBsAg) or large (pre-S1 + pre-S2 + S, L-HBsAg) surface antigens \[[@B9-ijms-17-01715]\] have been used as components of specific immunotherapeutic vaccines for chronic HBV carriers \[[@B10-ijms-17-01715],[@B11-ijms-17-01715]\]. Additionally, chimeric protein created by fusing the HBV core antigen (HBcAg) to the pre-S1 showed strong anti-HBc and moderate anti-pre-S1 immune responses \[[@B12-ijms-17-01715]\].

3. Plant-Based Expression System for Vaccine Development {#sec3-ijms-17-01715}
========================================================

Although vaccination is one of the most powerful and cost-competitive achievements, some vaccines may still have certain limitations related to maintenance of the cold chain, downstream processing costs, administration risk, and expensive scalability \[[@B13-ijms-17-01715],[@B14-ijms-17-01715],[@B15-ijms-17-01715],[@B16-ijms-17-01715],[@B17-ijms-17-01715]\]. From these reasons, the use of plant cells as alternative production platforms have received considerable attention in terms of intrinsic safety, scalability, and posttranslational modification of target proteins \[[@B17-ijms-17-01715],[@B18-ijms-17-01715]\]. Plant systems can be scaled up quickly to generate large quantities of the protein product, are not susceptible to contamination with known human or mammalian pathogens and are resistant to enzymatic digestion in the gastrointestinal tract. In addition, transgenic plants can be engineered to express and translate multiple proteins concurrently with appropriate folding and assembly into multimeric proteins, especially the posttranslational adjustments of antibodies. Not all recombinant antigens will benefit from plant-based systems, but the best production system for each recombinant protein should be chosen using a case-by-case approach \[[@B19-ijms-17-01715]\]. Merlin et al. \[[@B19-ijms-17-01715]\] proposed that plants are the most the beneficial for the production of four major categories of pharmaceutical proteins: ones that are required in large quantities, that need to be rapid-response, that require complex posttranslational modifications, or that are intended for oral delivery. Within these categories, they suggested appropriate candidates to meet a spectrum of research, development, commercial needs, such as human glutamic acid decarboxylase, Norwalk virus-like particles, monoclonal antibody 2G12, and human interleukin-6.

Those plant-made antigens have already been tested in clinical trials, with successful outcomes ([Table 1](#ijms-17-01715-t001){ref-type="table"}). The enzyme glucocerebrosidase for Gaucher's disease, the first PMF-derived enzyme "ELELYSO™", has been approved and marketed by Protalix in 2012. ELELYSO™ is based on the use of carrot cells to produce recombinant taliglucerase alpha, which is used in enzyme replacement therapy to treat adult patients. This special Food and Drug Administration (FDA) approval case was fast tracked based on its applicability to a rare genetic disease and the bioreactor production under stringent conditions \[[@B20-ijms-17-01715],[@B21-ijms-17-01715]\]. Medicago has ongoing phase II clinical trials for a plant-derived VLP quadrivalent seasonal influenza vaccine and an H5 pandemic influenza vaccine \[[@B22-ijms-17-01715]\]. They are focusing on VLP vaccine development. VLPs are self-assembled structures derived from viral antigens that mimic the native architecture of viruses but lack the viral genome and thus are not infective. Another important advantage as emerging vaccine is the more effective activation of key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory for long-lasting protection \[[@B22-ijms-17-01715],[@B23-ijms-17-01715]\]. Several reports on the expression of properly assembled VLPs at adequate levels have been published for the influenza virus \[[@B24-ijms-17-01715]\], human papillomavirus \[[@B25-ijms-17-01715]\], human immunodeficiency virus \[[@B26-ijms-17-01715],[@B27-ijms-17-01715]\], Norwalk virus \[[@B28-ijms-17-01715]\], and hepatitis B virus \[[@B26-ijms-17-01715],[@B29-ijms-17-01715],[@B30-ijms-17-01715]\]. In recent, VLPs have been applied in various fields, not only as vaccines \[[@B31-ijms-17-01715],[@B32-ijms-17-01715]\] but also as delivery agents for therapeutic medicine \[[@B33-ijms-17-01715],[@B34-ijms-17-01715],[@B35-ijms-17-01715],[@B36-ijms-17-01715]\]. In addition, Paul et al. \[[@B37-ijms-17-01715]\] summarized four major developments of molecular pharmaceuticals occurring in the world. More recently, Yao et al. \[[@B21-ijms-17-01715]\] reviewed the challenges and opportunities of plant molecular farming, including various examples of clinical trials from the perspectives of biosafety, appropriate expression systems, and possible and potential application.

Plant-based platforms including whole plant, organs or cell and expression technology to produce target antigens of interest are diverse \[[@B38-ijms-17-01715],[@B39-ijms-17-01715],[@B40-ijms-17-01715]\]. Representative plant species expressing the oral vaccine are potato, tomato, and tobacco; additionally, maize, rice, carrot, and soybean are also applied in this field \[[@B41-ijms-17-01715],[@B42-ijms-17-01715],[@B43-ijms-17-01715],[@B44-ijms-17-01715],[@B45-ijms-17-01715],[@B46-ijms-17-01715],[@B47-ijms-17-01715],[@B48-ijms-17-01715],[@B49-ijms-17-01715]\]. Those plants are mainly focused on traditional and usually eaten crops in human, because it is known that inexperienced plants sometimes have problems with certain plant allergies. Target antigen proteins were expressed by a plant cell nuclear genome expression system in these plant species. Edible plant vaccines are based on different parts of plants, such as fruits, seeds, and root vegetables. Such food vaccines are prepared directly without expensive purification of the antigens, which is essentially required for parenteral administration of vaccines \[[@B50-ijms-17-01715]\]. Therefore, the lyophilization of organs expressing stable antigens would facilitate their processing, purification and storage, reducing costs and allowing more practical vaccines. Although stable transformation into transgenic plants is commonly accepted, the low production level of the resultant recombinant protein remains an issue of concern. An efficient alternative to nuclear transformation for vaccine antigens and other therapeutic proteins is plastid transformation \[[@B51-ijms-17-01715]\]. The highest expression of transgenes, up to more than 70% of total soluble protein, are reported in chloroplast transformation \[[@B52-ijms-17-01715],[@B53-ijms-17-01715]\] Otherwise, the universal expression level in most studies has been 1% of total soluble protein (TSP) or 50 µg/g fresh leaf tissue \[[@B54-ijms-17-01715],[@B55-ijms-17-01715]\]. Chloroplast technology can also avoid the controversy related to transgene containment \[[@B40-ijms-17-01715]\] and express multigenes as single operon \[[@B56-ijms-17-01715]\]. Waheed et al. \[[@B40-ijms-17-01715]\] reviewed recent vaccine antigens against human diseases expressed via plastid genome since 2011. Two plant species, tobacco (15 different antigens) and lettuce (four different antigens), have mainly been used in plastid transformation. These results suggest that more industrial interest is needed to strengthen the research/academia-industry linkages in the chloroplast-based vaccine market.

Stable transformation has its own advantages such as reliable harvest of target proteins over multiple generations and optimized protocols for delivery of foreign genes into various plant species. Although there are problems with the time required, seed resources can be grown anywhere with minimal cost and labor once the plant has been developed for the first time \[[@B21-ijms-17-01715]\].

Most clinical trials, except for the three cases of ELEYSO, PRX-102, and recombinant human intrinsic factor, have used a tobacco-based transient expression system ([Table 1](#ijms-17-01715-t001){ref-type="table"}). In recent years, interest in transient expression has increased due to the containment of the system and the possibility of rapid upscaling due to the short interval between transformation and expression, which are attractive features for the industrial scale production and approval of the expressed products, e.g., the mass production of tobacco by Medicago and Kentucky BioProcessing. Pogue et al. \[[@B57-ijms-17-01715]\] reviewed plant-based transient expression systems for the production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product. Transient expression provides a safe and environmentally friendly system for both indoor and outdoor application with high speed and low cost of the genetic manipulation, rapid manufacturing cycles, and economical production. Transient production using an *Agrobacterium tumefaciens-*mediated transfer-DNA delivery system (Agro-infiltration) and/or virus-based replicating systems, the two dominant approaches, guarantees both the quality of the resulting purified products and the speed of development \[[@B57-ijms-17-01715],[@B58-ijms-17-01715]\]. Spiegel et al. \[[@B59-ijms-17-01715]\] demonstrate the application of the classical *Nicotiana benthamiana/A. tumefaciens* transient expression system to accelerate the development of a malaria vaccine candidate, with screens for expression, solubility, and stability using fluorescent fusion proteins. In Marin Viegas et al. \[[@B60-ijms-17-01715]\], a transient expression system for the production of human TG2 in *N. benthamiana* leaves was optimized, and the reactivity of plant-produced TG2 in a CD screening test was evaluated. Hence, transient expression performed in contained facilities satisfies good manufacturing practices, and quick expression can avoid the time-consuming stable transformation \[[@B58-ijms-17-01715],[@B61-ijms-17-01715]\]. In a comparison of productivity in terms of biomass production, Hiatt and Pauly \[[@B62-ijms-17-01715]\] reported that grams of product may take only two weeks plus a few weeks more. In large-scale biomanufacturing systems, recombinant proteins can be produced at levels of 200--1000 mg/kg fresh weight tissue in as little as three months \[[@B57-ijms-17-01715]\]. The transient expression of human Interleukin-6 in *N. benthamiana* (7.8% TSP) produces 80-fold more than stable expression in tobacco plants (0.3 mg/g fresh weight (FW)) \[[@B63-ijms-17-01715]\]. Conversely, hGAD65mut is expressed at higher levels in stable tobacco plants (143.6 µg/g FW) than in *N. benthamiana* (96.6 µg/g FW) \[[@B64-ijms-17-01715]\]. This result suggests that expression potential or level varies case by case, depending on the target protein.

4. Studies on Plant Vaccines {#sec4-ijms-17-01715}
============================

In last decade, there has been a considerable increase in the use of transgenic plants to generate recombinant proteins for medical and veterinary use ([Table 2](#ijms-17-01715-t002){ref-type="table"}). Research groups worldwide have attempted to develop more efficacious plant-derived vaccines for over 30 diseases, most frequently hepatitis B and influenza. In the case of hepatitis B, both stable and transient expression systems have been developed in various plants, including potato, lettuce, tobacco, tomato, carrot, and Arabidopsis for stable expression and *N. benthamiana* for transient expression. A detailed review of hepatitis B will be presented in the next part of this article.

Influenza is also a main target of this field because it is a widely distributed viral infection of humans and animals, and a new epidemic strain appears every one to two years. This pattern requires the production of new vaccines at the same frequency, and a promising solution is to establish a rapid, flexible, and safe system. The production of various antigens such as hemagglutinin (HA) and the extracellular domain of matrix protein 2 (M2e) has mainly focused on transient expression systems using *N. benthamiana* leaves. Using the Medicago "Proficia™" system, vaccine production can be initiated within less than three weeks from the identification of the genetic sequence of a pandemic or seasonal influenza strain \[[@B155-ijms-17-01715]\].

Vamvaka et al. \[[@B74-ijms-17-01715]\] reported the development of transgenic rice plant expressing the HIV-neutralizing antibody 2G12 in the endosperm (42 µg/g dry seed weight) to evaluate the potential of rice seeds as a vehicle for inexpensive microbicide production. Production is higher than the initial achievement of maize-derived 2G12 (30 µg/g) by Rademacher et al. \[[@B156-ijms-17-01715]\]. Rubio-Infante et al. \[[@B75-ijms-17-01715]\] demonstrated the immunogenic potential of tobacco chloroplast-derived multi-HIV in an oral immunization scheme and proposed it as a vaccine prototype capable of inducing broad immune responses as it carries various B and T cell epitopes from several HIV strains.

Dengue has become a significant public health problem, and the threat of Dengue fever is now increasing in temperate regions due to dramatic climate change. The rice codon-optimized consensus domain III of dengue virus envelope glycoprotein (E) has been fused to the M cell-binding peptide via agroinfiltration with a plant virus-based expression system \[[@B157-ijms-17-01715],[@B158-ijms-17-01715],[@B159-ijms-17-01715]\]. Carrying these results a step further, Kim et al. \[[@B159-ijms-17-01715]\] generated an Ebola RIC-based DENV vaccine in tobacco plants using a geminiviral vector expression system and reported its immunogenic properties as a self-adjuvanting dengue vaccine candidate. Previously, Phoolcharoen et al. \[[@B160-ijms-17-01715]\] reported that plant-expressed Ebola RIC protected mice against a lethal Ebola virus challenge.

The expression of subunit vaccines for animal viral diseases, such as avian influenza \[[@B98-ijms-17-01715],[@B161-ijms-17-01715]\], foot-and-mouth disease (FMD) \[[@B100-ijms-17-01715],[@B101-ijms-17-01715],[@B102-ijms-17-01715]\], and diarrhea \[[@B123-ijms-17-01715],[@B126-ijms-17-01715],[@B127-ijms-17-01715]\], which are considered to be the most important causes of economic losses in plants, has been frequently reported. The commercialization of veterinary vaccine is relatively easy compared with that of human vaccines. To date, four cases in clinical trials are ready to enter the market. Recombinant plant viral hamagglutinin-neuraminidase (HN) protein of the Newcastle disease virus (approved by United States Department of Agriculture (USDA)) and a mixture of antiviral vaccines have been prepared by Dow Agro Sciences. A plant anti-rabies vaccine (completion of phase I) has been developed by Thomas Jefferson University. Chicken coccidiosis is in the second phase of clinical trials run by the Canadian Guardian Biosciences company. For the FMD vaccine, *N. benthamiana*, tomato, and rice have been used for both transient and stable transformation. Most recently, Muthamilselvan et al. \[[@B99-ijms-17-01715]\] have presented an important advance with 2.1 mg/20 g fresh weight of plant callus-based biomass in the cost-effective large-scale production of immunopeptide vaccines against FMD. They established transgenic cell-suspension cultures from *N. benthamiana* leaves expressing FMDV VP1 and gene silencing suppressor p19 and then validated the efficacy using immunized guinea pigs that produced humoral antibodies. Lim et al. \[[@B100-ijms-17-01715]\] developed an SYCMV-derived vector containing FMDV VP1, which was expressed successfully in soybean plants by infiltration.

Diarrhea, a representative infectious disease caused by rotavirus and diarrhea virus, is also being studied. Various groups have expressed rotavirus capsid proteins (VP2, -4, -6, -7, and -8) in plants. Most studies have introduced VP6, which forms the intermediate capsid, as a vaccine epitope into different plant species, including *N. benthamiana*, tomato, and *Medicago sativa*. Pera et al. \[[@B162-ijms-17-01715]\] suggest that the highly immunogenic VP8 epitopes produced in *N. benthamiana* are candidates for a subunit vaccine, specifically for the G9P rotavirus strain.

5. Production of HBV Antigens in a Plant System {#sec5-ijms-17-01715}
===============================================

The greatest problem of plant-derived vaccine development is the extremely low expression level of the foreign protein in plants. For this reason, many researchers have studied how to improve protein expression levels in plants. In the case of plant-derived HBV vaccines, the first report was on the expression of the small hepatitis B surface antigen (S-HBsAg) in transgenic tobacco plants. In this report, the HBsAg produced in transgenic tobacco was antigenically and physically similar to the HBsAg particles derived from human serum and recombinant yeast \[[@B163-ijms-17-01715]\]. Afterward, many research groups attempted HBsAg expression in different tissues and plant species, such as tobacco, potato, lettuce, soybean, lupine, maize, tomato, peanut and *Laminaria japonica* ([Table 3](#ijms-17-01715-t003){ref-type="table"}). In the transgenic tobacco plant transformed with the S-HBsAg gene controlled by the 35S promoter, expression levels were very low: less than 0.01% total soluble protein and less than 10 ng/g fresh weight in leaf tissues. The expression levels of S-HBsAg in other plant species were not significantly higher; in some species, expression levels were even lower than in tobacco. To improve vaccine production in plants, the most widely used strategies involve: (1) suitable promoters, such as strong constitutive promoters, tissue-specific promoters and promoters that are inducible by environmental factors; (2) targeting systems to specific organelles; (3) optimized codon usage; (4) alternative polyadenylation signals; (5) increased translation efficiency using leader sequences; and (6) different vector systems. Many HBsAg-overexpressing transgenic plants have been developed using strong constitutive promoters, such as the 35S promoter with enhancer \[[@B164-ijms-17-01715],[@B165-ijms-17-01715],[@B166-ijms-17-01715]\]. In addition to tissue-specific promoters, the patatin promoter for potato tuber \[[@B165-ijms-17-01715],[@B167-ijms-17-01715]\], globulin promoter for maize seed \[[@B168-ijms-17-01715]\] and fruit-specific promoters \[[@B169-ijms-17-01715],[@B170-ijms-17-01715]\] were used. Specific organelle-, endoplasmic reticulum (ER)-, vacuole- and chloroplast-targeted strategies have also been tried \[[@B167-ijms-17-01715],[@B171-ijms-17-01715]\].

The HBsAg has been expressed in non-edible plants, such as tobacco, using four different expression cassettes: the HBsAg gene without ER retention signal (HBS), the HBsAg gene with ER retention signal (HER), and each gene controlled by the ubiquitin promoter (UBQ) or ethylene forming enzyme promoter (EFE) \[[@B172-ijms-17-01715]\]. In this report, the maximum expression level (19.4 ng/g FW of leaves) was observed in EFE-HBS transformed plant growth in vitro, but a higher proportion of the particulate form of the antigen was observed when it was expressed with an ER retention signal. The EFE promoter is more effective in in vitro-cultured plantlets, whereas the UBQ promoter is more effective in greenhouse-grown plantlets. The maximum expression level was 2 µg/g FW in the UBQ-HER transformed NT-l cell suspension culture \[[@B173-ijms-17-01715]\]. The expression level was increased up to 8 µg/g FW using HBsAg fused with the 3′ region from the soybean vegetative storage protein gene and was controlled by a chimeric ocs-mas promoter. Upon transformation into a soybean cell culture using the same vector, the maximum expression level was 74 µg/g FW \[[@B174-ijms-17-01715]\].

HBsAg has been expressed in vegetative crops, such as potato, tomato, soybean and lettuce. The expression level of transgenic potato tubers was 1--11 µg/g FW. The highest expression in a tuber was developed using a construct driven by the CaMV 35S promoter with dual enhancers, the tobacco etch virus 5′-UTR, and the 3′ region from the soybean vegetative storage protein gene \[[@B165-ijms-17-01715]\]. Expression level of HBV-protein in potato was little increased when controlled by the tuber specific promoter \[[@B167-ijms-17-01715]\]. Target DNA is inserted into a genomic DNA as a random event when a using *Agrobacterium*-mediated transformation. For this reason, it is difficult to conclude what is the best method for increase of HBV-protein expression level because differences in the expression level between the transgenic lines even with the same vector construction. Expression in tomato fruit has been reported at 0.5 µg/g dry weight. To achieve a higher level of expression, several strong and inducible promoters, such as the enhanced dual 35S, UBQ and EFE promoters, were tested, as well as organelle targeting sequences. The greatest improvement resulted from the HBsAg gene with an ER retention signal controlled by EFE promoter \[[@B169-ijms-17-01715]\]. Sunil Kumar et al. \[[@B170-ijms-17-01715]\] reported HBsAg transformation in banana. The maximum expression in banana leaves has been reported at 38 ng/g FW. The expression levels in banana fruits were not presented in this report, but the expression level was presumably lower than in the leaf tissue. As with leafy vegetables, a variety of expression technologies have not yet been applied. In lettuce, the maximum expression level was 60 µg/g FW, which is the maximum anti-HBsAg antibody titer of 300 mIU in immunized mice serum \[[@B188-ijms-17-01715],[@B189-ijms-17-01715],[@B201-ijms-17-01715]\]. Upon transformation into a soybean cell culture using a construct of HBsAg fused with the 3′ region from the soybean vegetative storage protein gene and as controlled by a chimeric ocs-mas promoter, the maximum expression level was 74 µg/g FW \[[@B174-ijms-17-01715]\].

Grains are a further option for the expression of candidate vaccine antigens. They have long stability of expressed recombinant proteins with low water content \[[@B212-ijms-17-01715]\]. In maize seed, the maximum expression has been reported at 0.51% of total soluble protein (approximately 80 µg/g FW). This level of expression was achieved using a barley alpha amylase signal sequence-fused S-HBsAg gene with a 3× globulin1 promoter \[[@B168-ijms-17-01715]\]. All of the results suggest that the expression levels of HBsAg are highly variable and depend on plant species, tissue types and culture conditions.

The major recombinant hepatitis B vaccines contain S-HBsAg; therefore, the expression of this protein has been the focus in plants. The proteins preS2-S, M-HBsAg, and preS1-preS2-S, L-HBsAg, have been much less studied than S-HBsAg. M-HBsAg and L-HBsAg have been transformed into potato, tomato, and tobacco ([Table 3](#ijms-17-01715-t003){ref-type="table"}). Although the expression was optimized using suitable promoters, leader sequences and targeting signals, the expression levels of M-/L-HBsAg were lower than for S-HBsAg. However, HBcAg induces a heightened immune response \[[@B213-ijms-17-01715],[@B214-ijms-17-01715]\] and spontaneously assembles into capsid-like particles \[[@B215-ijms-17-01715]\]. For these reasons, efforts devoted to the production of an anti-HBV vaccine have focused on HBcAg in the last few years. Especially, HBcAg has been abundantly produced using transient expression systems mediated by ICON binary vectors \[[@B208-ijms-17-01715]\] or viral vector systems \[[@B209-ijms-17-01715]\] ([Table 3](#ijms-17-01715-t003){ref-type="table"}).

6. Breakthroughs Regarding the Weak Points of Plant-Derived HBV Antigens as Injected Vaccines {#sec6-ijms-17-01715}
=============================================================================================

Transgenic tobacco plants-derived HBsAg was antigenically and physically similar to the human serum and recombinant yeast derived-HBsAg particles \[[@B163-ijms-17-01715]\]. To analyze the immunological response in vivo, tobacco-expressed HBsAg was purified and injected into BALB/c mice. The anti-HepB response to the tobacco-derived HBsAg was qualitatively similar to the response obtained by immunizing mice with commercialized yeast-derived HBsAg vaccine \[[@B175-ijms-17-01715]\]. These results showed a possibility of developing injected vaccines using plant-expressed HBsAg.

Due to differences of the manufacturing processes between companies, the amount of HBsAg protein per dose differs among the various HBV vaccine products \[[@B216-ijms-17-01715]\]. For this reason, there is no international standard for the HBsAg protein quantity in vaccines, but there is a standard based on protective efficacy of vaccination related to the anti-HepB antibodies induction. An anti-HBsAg of ≥10 mIU/mL measured 1--3 months after the last dose of the vaccine are considered to be immune to HepB. Although no international standard of antigen concentration is defined, considering the feasibility and cost-effectiveness of the injected vaccine, the concentration of antigen should be over 40 μg/mL \[[@B217-ijms-17-01715]\].

Despite many attempts to increase HBsAg expression in transgenic plants, the expression level remains too low for use as an injected vaccine. The currently used HBV vaccine contains HBsAg and is produced by yeast cells. The yeast-derived HBV vaccine can be supplied inexpensively (\$1--20 per single dose \[[@B218-ijms-17-01715]\]); therefore, it is difficult for plant-derived vaccines to have a competitive price. However, plant suspension cultures may be used as an alternative to yeast to produce antigens for purification. Expression levels have approached 74 μg/g FW (22 mg/L culture medium) in transgenic soybean culture \[[@B174-ijms-17-01715]\]. Although the expression level (8 μg/g FW) was lower in transgenic tobacco cell suspension culture than in soybean \[[@B174-ijms-17-01715]\], the former has been used to secrete HBsAg into the culture medium, with a six-fold increase in secretion in response to jasmonic acid or salicylic acid treatment during cell culture, and the amount of antigen secreted was 180 μg/L medium \[[@B170-ijms-17-01715]\].

Another breakthrough regarding expression problems was achieved through the utilization of virus-based transient expression systems for the robust production of HBV antigens, such as S-HBsAg and HBcAg, with yields as high as 2 mg/g FW \[[@B208-ijms-17-01715],[@B209-ijms-17-01715],[@B211-ijms-17-01715]\]. Tobacco-derived proteins showing the maximum anti-HBsAg antibody titer of 1165 mIU in immunized mice serum \[[@B211-ijms-17-01715]\] are preferred the application of injection after purification process, rather than oral administration in order to remove many toxic alkaloids and phenolic substances which have a tobacco plant \[[@B219-ijms-17-01715]\]. However, improvements of several orders of magnitude are still needed for plant cell culture systems to be competitive, particularly given the slow growth rates of plant cells compared with yeast.

In transgenic suspension cell culture, the formation of VLPs by HBV antigens made it possible to exploit relatively inexpensive protein purification techniques, such as the sucrose gradient \[[@B174-ijms-17-01715],[@B182-ijms-17-01715],[@B184-ijms-17-01715]\] or cesium chloride gradient ultracentrifugation \[[@B173-ijms-17-01715]\]. The highest expressed soybean cell culture was used for antigen purification, and the antigen was suitable for injection \[[@B174-ijms-17-01715]\], but the yield remained unsatisfactory and was not cost-effective.

7. Breakthroughs Regarding the Weak Points of Plant-Derived HBV Antigens as Oral Vaccines {#sec7-ijms-17-01715}
=========================================================================================

The biggest advantage of edible plant-derived vaccines is their easy application to oral delivery. The benefits of plant-derived edible vaccines are as follows: (1) during oral delivery, plant-derived vaccines are protected in the stomach by plant cell wall and slow release in the gut; (2) the plant tissue expressing antigen may be used as raw or dried food; (3) capsules can also be made from partially or fully purified vaccine proteins; (4) no need for cold chain systems for storage and delivery of the plant tissues or extracts; and (5) the plant-derived vaccines are cost efficient compared with traditional vaccines.

Edible plant-derived HBV antigens have been administered by oral injection or feeding in mice with/without adjuvants \[[@B41-ijms-17-01715],[@B165-ijms-17-01715],[@B166-ijms-17-01715],[@B167-ijms-17-01715],[@B193-ijms-17-01715]\]. An oral vaccine candidate has also been administered to human volunteers in small-scale clinical trials without adjuvants. The first trial was administered to three human volunteers in row lettuce leaves in two doses (0.5--1 μg of S-HBsAg/dose) without the use of an adjuvant. All volunteers responded, with two of them having serum responses in excess of the protective minimum level (10 mIU/mL of serum). However, the antibody levels declined rapidly \[[@B187-ijms-17-01715],[@B220-ijms-17-01715]\]. In the second trial, previously vaccinated human volunteers were fed two or three doses of 100 g of raw potato tubers (approximately 1 mg of the S-HBsAg/dose). More than half of the subjects showed increased antibody titers \[[@B221-ijms-17-01715]\]. The animal experiments and trials showed the potential for plant-derived HBV antigens to be used as an oral vaccine for the prevention of HBV, but there remain many problems to be solved for practical application, such as the administration of bulky plant material, declining long-term responses, individual differences in the immune response and the difficulty of defining the antigen dose \[[@B222-ijms-17-01715]\].

The expression level of plant-derived HBV antigen is only 1/20--1/25 of the expression of yeast-derived HBV antigen; however, the expression yield and plant production scale are still increasing \[[@B223-ijms-17-01715],[@B224-ijms-17-01715]\]. Tomato is possible intake without any processing or cooking. Therefore, tomato fruit is a very attractive crop to develop an oral vaccine. According to the study to date, the expression level of HBV antigen was very low as 10 ng/g FW ([Table 3](#ijms-17-01715-t003){ref-type="table"}). The maximum titers of anti-HBsAg antibody in serum is 300 mIU using oral application. This antibody yield was high compared to the expression level of HBV antigen in tomato fruits \[[@B225-ijms-17-01715]\]. HBV antigen expression in maize produced much higher levels of antigen, and the palatability and digestibility were better than for potato. That is, cereal crops can easily transport or storage in dry state. In addition, the maize system induced a strong immune response with 4632 mIU of maximum titer by both injection and oral administration \[[@B193-ijms-17-01715],[@B194-ijms-17-01715]\]. This result suggests the possibility of providing a raw material for thermostable formulation at \$0.01 per dose \[[@B193-ijms-17-01715]\]. Plant components such as saponin, flavonoids, and plant oils also function as adjuvants \[[@B226-ijms-17-01715],[@B227-ijms-17-01715],[@B228-ijms-17-01715]\] and help maintain the immune response in the long term \[[@B195-ijms-17-01715]\].

The lyophilization method is an excellent way to increase the stability and shelf life of the plant-derived vaccines. In the previous study, the storage stability of lyophilized powder form was limited at 4 °C \[[@B189-ijms-17-01715]\]. In a recent study, successful long-term storage at 37 °C was achieved though improvements in the process \[[@B229-ijms-17-01715]\]. It is easier to control the concentration and standardize antigen doses and process the antigen into a tablet or capsule form using a powdered tissue instead of freeze-drying \[[@B188-ijms-17-01715]\].

8. Conclusions {#sec8-ijms-17-01715}
==============

Despite over 20 years of effort, no commercial plant-based anti-HBV vaccine has been developed. To commercialize a plant-derived HBV vaccine, several points should be considered. First, the greatest barrier is the low expression levels of HBV antigen in plants; however, expression yield and plant production scale can still be increased using plant expression vector optimization, which should be focused on the target plant. The process can also be more competitive by improving the plant-derived antigen to increase the immune response to the vaccine. Second, an HBV antigen expressed in an edible plant has the advantage of being usable as an oral vaccine without processing. It is first necessary to analyze the characteristics of the target plants and the expressed protein for the development of an oral vaccine because plant components, secondary metabolites and foreign protein expression characteristics vary with plant species. To obtain feasible and cost-effective vaccines, the target plants for edible vaccines should have a long shelf life, be heat stable and be edible as a raw material. Candidate grain crops are maize and rice; candidate vegetative crops are tomato and banana. Third, consideration should be made of the public's acceptance of GM crops, especially plant-derived edible vaccines. For injected vaccine development, the most cost-effective method is a suspension culture in a closed environment, according to the regulations of good manufacturing practice. Further safety of plant-derived vaccines can be obtained by following the same regulations established for traditional vaccines. In addition, for oral vaccines produced from GM crops, environmental risk assessment and human risk assessment should be performed. For these reasons, plant-derived oral vaccines cannot be called cost efficient compared with traditional vaccines, and the current concern over the use of GM plants is now affecting research in this field.
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###### 

Clinical studies of plant-derived vaccines (data from US National Institutes of Health clinical trial).

  Application                                                                                                                        Study                                                                                                                                      Status                                        Sponsor
  ---------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------- ----------------------------------------------------------------------
  **Anthrax (1)**                                                                                                                    A Phase I Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults   Phase I (2015), ongoing (NCT02239172)         Fraunhofer, Center for Molecular Biotechnology
  **Influenza, Human (3)**                                                                                                           Safety and Immunogenicity of a Recombinant H5N1 Vaccine in Adults                                                                          Unknown (2011), (NCT01250795)                 Fraunhofer, Center for Molecular Biotechnology
  Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults   Phase II (2015), ongoing (NCT02233816)                                                                                                     Medicago                                      
  Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population   Phase II (2015), ongoing (NCT02236052)                                                                                                     Medicago                                      
  **Malaria**                                                                                                                        Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults                         Phase I (2015), ongoing (NCT02013687)         Fraunhofer, Center for Molecular Biotechnology
  **Gaucher Disease**                                                                                                                A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease                           Phases III, completed (2012) (NCT00376168)    Protalix
  **Ebola Virus**                                                                                                                    Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection                                              Phase I,II, recruiting (2015) (NCT02363322)   Zmapp, National Institute of Allergy and Infectious Diseases (NIAID)
  **Fabry disease**                                                                                                                  An Extension of a Phase I/II, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients                                            Phase I,II, enrolling (2015) (NCT01769001)    Protalix
  **Human Immunodeficiency Virus**                                                                                                   A Safety Study Of A Single Vaginal Administration of P2G12 Antibody In Healthy Female Subjects                                             Phase I, completed (NCT01403792)              University of Surrey (European Commission)
  **Influenza A Subtype H5N1 Infection**                                                                                             H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers                                                                                  Phase I, completed (NCT01657929)              Infectious Disease Research Institute (IDRI), Medicago
  **Vitamin B12 Deficiency**                                                                                                         Can Recombinant Human Intrinsic Factor Be Used for Evaluation of the Vitamin B12 Absorption?                                               Phase II, completed (NCT00279552)             University of Aarhus
  **Healthy**                                                                                                                        Safety and Immunogenicity of a Recombinant H5N1 Vaccine in Adults                                                                          Phase I, unknown (NCT01250795)                Fraunhofer, Center for Molecular Biotechnology

ijms-17-01715-t002_Table 2

###### 

Published studies on plant-derived antigens for last decade.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target Disease                                                                 Antigen                                                                       Host/Expression System          Binary Vector/Agrobacterium Strain       Reference
  ------------------------------------------------------------------------------ ----------------------------------------------------------------------------- ------------------------------- ---------------------------------------- ---------------------------
  Malaria                                                                        Multi-domain antigen                                                          *N. benthamiana*/transient      pTRAkc-ERH/GV3101                        \[[@B59-ijms-17-01715]\]

  pfGAP50                                                                        *N. benthamiana*/transient                                                    pMP90RK/GV3101                  \[[@B65-ijms-17-01715]\]                 

  Pfs25, Pfs230_C0                                                               *N. benthamiana*/transient                                                    pTRAkc-ERH/GV3101               \[[@B66-ijms-17-01715]\]                 

  Multi-domain antigen (PfCSP, PfTRAP, PfCelTOS)                                 *N. benthamiana*/transient                                                    pMO90RK/GV3101                  \[[@B67-ijms-17-01715]\]                 

  Pf38                                                                           *N. benthamiana*/transient                                                    pTRAkc-ERH/GV3101               \[[@B68-ijms-17-01715]\]                 

  Pfs25                                                                          *N. benthamiana*/transient                                                    pGRD4/GV3101                    \[[@B69-ijms-17-01715]\]                 

  PfCP-2.9                                                                       Tomato/transgenic                                                             pPS1/LBA4404                    \[[@B70-ijms-17-01715]\]                 

  PyMSP1~19~                                                                     *N. benthamiana*/transient                                                    pICH11599/GV3101                \[[@B71-ijms-17-01715]\]                 

  Pfs230                                                                         *N. benthamiana*/transient                                                    pGRD4/GV3101                    \[[@B72-ijms-17-01715]\]                 

  PyMSP4/5                                                                       *N. benthamiana*/transient                                                    pICH11599/GV3101                \[[@B73-ijms-17-01715]\]                 

  HIV                                                                            2G12                                                                          Rice endosperm/transgenic       pTRA/n.a. \*                             \[[@B74-ijms-17-01715]\]

  Gp120 and gp41                                                                 *N. tabacum*/transplastomic                                                   n.a.                            \[[@B75-ijms-17-01715]\]                 

  p24                                                                            *A. thaliana*/transgenic\                                                     pGreen0229/EHA105               \[[@B76-ijms-17-01715]\]                 
                                                                                 *D. carota*/transgenic                                                                                                                                 

  Multi-HIV (gp120 and gp41)                                                     *N. tabacum*/transplastomic                                                   pKCZ-derived/n.a.               \[[@B77-ijms-17-01715]\]                 

  MPR of the gp41                                                                *N. benthamiana*/transgenic                                                   pTM096/LBA4404                  \[[@B78-ijms-17-01715]\]                 

  Nef                                                                            *N. tabacum*/transgenic                                                       pGreenII0179/GV3101             \[[@B79-ijms-17-01715]\]                 

  p17/p24                                                                        *N. benthamiana*/transient                                                    pTRAc/GV3101                    \[[@B80-ijms-17-01715]\]                 

  Influenza                                                                      M2e (extracellular domain of matriz protein 2)                                *N. benthamiana*/transient      pA7248AMV/GV3101                         \[[@B81-ijms-17-01715]\]

  M2e (ectodomain of matrix protein 2)                                           Duckweed/transgenic                                                           pBI121/n.a.                     \[[@B82-ijms-17-01715]\]                 

  H5 HA                                                                          Arabidopsis/transformation                                                    326-Bip/n.a.                    \[[@B83-ijms-17-01715]\]                 

  H5 HA (H5 Hemagglutinin)                                                       *N. benthamiana*/transient                                                    n.a./GV3101                     \[[@B84-ijms-17-01715]\]                 

  H1 & H5 HA                                                                     *N. benthamiana*/transient                                                    n.a.                            \[[@B85-ijms-17-01715]\]                 

  H7 HA                                                                          *N. benthamiana*/transient                                                    n.a.                            \[[@B86-ijms-17-01715]\]                 

  H1 & H5 HA                                                                     *N. benthamiana*/transient                                                    n.a.                            \[[@B87-ijms-17-01715]\]                 

  HA                                                                             *N. benthamiana*/transient                                                    n.a.                            \[[@B88-ijms-17-01715]\]                 

  HA                                                                             *N. benthamiana*/transient                                                    pGRD4/GV3101                    \[[@B89-ijms-17-01715]\]                 

  HAC1                                                                           *N. benthamiana*/transient                                                    n.a.                            \[[@B90-ijms-17-01715]\]                 

  H5 HA                                                                          *N. benthamiana*/transient                                                    pTRA/GV3101                     \[[@B91-ijms-17-01715]\]                 

  H1 HA                                                                          *N. benthamiana*/-                                                            n.a.                            \[[@B92-ijms-17-01715]\]                 

  M2eHBc                                                                         *N. benthamiana*/transient                                                    pGEM/GV3101                     \[[@B93-ijms-17-01715]\]                 

  H5 HA                                                                          *N. benthamiana*/transient                                                    n.a.                            \[[@B94-ijms-17-01715]\]                 

  H3 HA                                                                          *N. benthamiana*/transient                                                    pBID4/GV3101                    \[[@B95-ijms-17-01715]\]                 

  H3 HA                                                                          *N. benthamiana*/transient                                                    pBID4/GV3101                    \[[@B96-ijms-17-01715]\]                 

  Avian influenza                                                                rHA0                                                                          *N. benthamiana*/transient      magnICON, TMV                            \[[@B97-ijms-17-01715]\]

  Hemagglutinin M2                                                               *N. benthamiana*/transient                                                    CMV                             \[[@B98-ijms-17-01715]\]                 

  Foot-and-mouth disease                                                         VP1                                                                           *N. benthamiana* cell/stable    pBVP1/GV3850                             \[[@B99-ijms-17-01715]\]

  VP1                                                                            Soybean/transient                                                             pSYCMV-FMDV                     \[[@B100-ijms-17-01715]\]                

  FMDV VP1                                                                       Crotalaria/transgenic                                                         n.a.                            \[[@B101-ijms-17-01715]\]                

  VP1                                                                            Rice/transgenic                                                               n.a.                            \[[@B102-ijms-17-01715]\]                

  P1-2A3C                                                                        Tomato/transgenic                                                             pBin438/GV3101                  \[[@B103-ijms-17-01715]\]                

  FMDV VP1                                                                       *Chenopodium quinoa* *(C. quinoa*)/*N. benthamiana*/transient                 CMV-based pBVP1                 \[[@B104-ijms-17-01715]\]                

  Colorectal cancer                                                              GA733-Fc                                                                      *N. tabacum*/transgenic         T-easy/LBA4404                           \[[@B105-ijms-17-01715]\]

  GA733-FcK                                                                      *N. tabacum*/transgenic                                                       pBIN-Plus/LBA4404               \[[@B106-ijms-17-01715]\]                

  GA733K, GA733-FcK, and GA733-Fc                                                *N. tabacum*/transgenic                                                       pBIN-Plus/LBA4404               \[[@B107-ijms-17-01715]\]                

  GA733                                                                          *N. tabacum*/transgenic\                                                      pBIN-Plus/LBA4404\              \[[@B108-ijms-17-01715]\]                
                                                                                 *Beta vulgaris*/transient                                                     pICH11599/GV3101                                                         

  Mosaic diseases                                                                ALSV and BYMV                                                                 *N. benthamiana*/-              n.a.                                     \[[@B109-ijms-17-01715]\]

  Anthrax                                                                        PA (Protective antigen)                                                       Tobacco/transgenic              pCHV-RKB/n.a.                            \[[@B110-ijms-17-01715]\]

  PA (dIV) (Protective antigen Domain IV)                                        n.a.                                                                          pCambia1303/GV2260              \[[@B111-ijms-17-01715]\]                

  Polysaccharide encapsulated bacteria                                           cps3S                                                                         *N. tabacum*/transgenic         pCambia2301/GV3101                       \[[@B112-ijms-17-01715]\]

  Atherosclerosis                                                                ApoB100, CETP                                                                 *N. tabacum*/transgenic         n.a.                                     \[[@B113-ijms-17-01715]\]

  West Nile Virus (WNV)                                                          Domain III (DIII) of WNV E protein                                            *N. benthamiana*/transient      pIC11599 of the MagnICON system/GV3101   \[[@B114-ijms-17-01715]\]

  Hemophilia                                                                     Factor VIII (FVIII)                                                           *N. tabacum*/transgenic         pLD-CTB/n.a.                             \[[@B115-ijms-17-01715]\]

  Swine edema                                                                    Shiga toxin 2e B (Stx2e)                                                      *L. sativa*/transgenic          pBI121/n.a.                              \[[@B116-ijms-17-01715]\]

  Shiga toxin 2e B                                                               *L. sativa*/transgenic, transient *N. tabacum*/transgenic, transient          pBI121/n.a.                     \[[@B117-ijms-17-01715]\]                

  Hemorrhagic colitis & hemolytic-uremic syndrome (*Escherichia coli* O157:H7)   EIT                                                                           *N. tabacum*/transgenic         pVSR326/n.a.                             \[[@B118-ijms-17-01715]\]

  Cholera                                                                        CTB                                                                           *O. sativa*/transgenic          pZ2028/n.a.                              \[[@B119-ijms-17-01715]\]

  CTB-As16                                                                       *O. sativa*/transgenic                                                        pGTV/EHA105                     \[[@B120-ijms-17-01715]\]                

  CTB-FimA                                                                       *S. tuberosum*/transgenic                                                     pPCV701/n.a.                    \[[@B121-ijms-17-01715]\]                

  Infectious Bursal Disease                                                      VP2                                                                           *N. benthamiana*/transient      pBINPLUS/n.a.                            \[[@B122-ijms-17-01715]\]

  Bovine rotavirus infection                                                     VP8                                                                           *N. tabacum*/transgenic         pBSW-utr/n.a.                            \[[@B123-ijms-17-01715]\]

  RHD                                                                            VP60                                                                          *S. tuberosum*/transgenic       pGK/LBA4404                              \[[@B124-ijms-17-01715]\]

  Diarrhea                                                                       Rotavirus VP6                                                                 *C. amaranticolor*/transgenic   pGEM/n.a.                                \[[@B125-ijms-17-01715]\]

  Bovine viral diarrhea                                                          E2                                                                            *M. sativa*/transgenic          pBI121/LBA4404                           \[[@B126-ijms-17-01715]\]

  (tE2) truncated version of the glycoprotein E2                                 *N. tabacum*/transient                                                        pK7WG2/EHA105                   \[[@B127-ijms-17-01715]\]                

  Heat labile toxin                                                              B subunit of the heat labile toxin (LTB)                                      *N. benthamiana*/transient\     pBinPlus/n.a.                            \[[@B128-ijms-17-01715]\]
                                                                                                                                                               *P. parodii*/transgenic                                                  

  LTB                                                                            *N. tabacum*/transgenic\                                                      pBinPlus/LBA9402                \[[@B129-ijms-17-01715]\]                
                                                                                 *P. Parodii*/transgenic\                                                                                                                               
                                                                                 *S. lycopersicum*/transgenic                                                                                                                           

  LTB                                                                            *N. benthamiana*/transient\                                                   pICH11599/GV3101\               \[[@B130-ijms-17-01715]\]                
                                                                                 *P. parodii*/transgenic\                                                      pBinPlus/LBA9402\                                                        
                                                                                 *S. lycopersicum*/transgenic                                                  pCLTB/EHA105                                                             

  Coccidiosis                                                                    EtMIC1 and EtMIC2                                                             *N. tabacum*/transient          pTRA ERH/GV3101                          \[[@B131-ijms-17-01715]\]

  PRRS                                                                           PRRSV matrix (M) protein                                                      Maize callus/transgenic         pAHC25/n.a.                              \[[@B132-ijms-17-01715]\]

  HPV                                                                            HPV16                                                                         *N. benthamiana*/transient      pBID4/GV3101                             \[[@B133-ijms-17-01715]\]

  HPV16 L1 (fused with LTB)                                                      *N. tabacum*/transgenic                                                       pPNG1014_MCS120/n.a.            \[[@B134-ijms-17-01715]\]                

  HPV16 E7                                                                       *N. tabacum*/transgenic\                                                      pBID4/A4                        \[[@B135-ijms-17-01715]\]                
                                                                                 *N. benthamiana*/transient                                                                                                                             

  Gastroenteritis                                                                VP4 and VP7                                                                   *N. benthamiana*/transient      n.a.                                     \[[@B136-ijms-17-01715]\]

  *OmpA* of *Salmonella typhimurium*                                             Alfalfa/transgenic                                                            pBI121/LBA4404                  \[[@B137-ijms-17-01715]\]                

  VP7                                                                            *S. tuberosum*/transgenic                                                     pBI121/LBA4404                  \[[@B45-ijms-17-01715]\]                 

  Peptic ulceration and gastric cancer (*Helicobacter pylori*)                   *Helicobacter pylori* TonB                                                    *A. thaliana*/transgenic        pPCV742/n.a.                             \[[@B138-ijms-17-01715]\]

  Plague                                                                         F1 and V antigens from *Y. pestis*                                            Lettuce/transgenic              pBI121/LBA4404                           \[[@B139-ijms-17-01715]\]

  F1-V                                                                           *S. lycopersicum*/transgenic                                                  n.a.                            \[[@B140-ijms-17-01715]\]                

  F1-V                                                                           *N. benthamiana*/transgenic                                                   n.a.                            \[[@B141-ijms-17-01715]\]                

  F1-V                                                                           *N. tabacum*/transgenic                                                       pLD/n.a.                        \[[@B142-ijms-17-01715]\]                

  F1 and LcrV                                                                    *N. benthamiana*/transient                                                    pBID4/A4                        \[[@B143-ijms-17-01715]\]                

  F1-V                                                                           *N. benthamiana*/transient\                                                   pGPTV/LBA4404                   \[[@B144-ijms-17-01715]\]                
                                                                                 *L. esculentum*/transgenic                                                                                                                             

  F1-V                                                                           *N. benthamiana*/transient                                                    pICH11599/n.a.                  \[[@B43-ijms-17-01715]\]                 

  Tuberculosis                                                                   Ag85B/ESAT-6                                                                  *N. tabacum*/transgenic         pGEM(T)-easy/C58C1                       \[[@B145-ijms-17-01715]\]

  ESAT6:Ag85B                                                                    *N. benthamiana*/transient                                                    pBin19/GV3101                   \[[@B146-ijms-17-01715]\]                

  ESAT-6                                                                         *A. thaliana*/transgenic                                                      n.a.                            \[[@B147-ijms-17-01715]\]                

  Newcastle disease                                                              (HN) Hemagglutinin neuraminidase                                              *N. tabacum*/transgenic         n.a.                                     \[[@B148-ijms-17-01715]\]

  Avian reovirus                                                                 σC                                                                            *A. thaliana*/transgenic        n.a.                                     \[[@B149-ijms-17-01715]\]

  Diphtheria Tetanus Pertussis (DTP)                                             DT (diphtheria toxin) TetC (fragment C antigen) PTX S1 (subunit S1 antigen)   *N. tabacum*/transgenic\        pBinPlus/LBA4404                         \[[@B150-ijms-17-01715]\]
                                                                                                                                                               *D. carota*/transgenic                                                   

  RSV (Respiratory Syncytial Virus)                                              RSV-F                                                                         *S. lycopersicum*/transgenic    pJSS-4/n.a.                              \[[@B151-ijms-17-01715]\]

  Poxvirus infection                                                             pB5                                                                           *N. benthamiana*/transient      n.a./GV3101                              \[[@B152-ijms-17-01715]\]

  SARS                                                                           S1                                                                            Tobacco/transgenic\             n.a.                                     \[[@B153-ijms-17-01715]\]
                                                                                                                                                               Lettuce/transgenic                                                       

  Follicular lymphoma                                                            Idiotypic Ig (tumor-specific antigen)                                         *N. benthamiana*/transient      magnICON/ICF 320                         \[[@B154-ijms-17-01715]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* n.a.: Not available; HIV, Human Immunodeficiency; FMDV, Foot-and-mouth disease virus; EIT, Trivalent recombinant protein; CTB, Cholera toxin B subunit; RHD, Rabbit haemorrhagic disease (RHD); HPV, Human papillomavirus; SARS, Severe acute respiratory syndrome.
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###### 

Published studies on plant-derived hepatitis B virus (HBV) antigens and expression levels.

  Antigen                           Host Plant/Expression System   Binary Vector/Agrobacterium Strain   Promoter/Targeting                    Maximum Yield                                                                                                                                      Application and Results                                    Reference
  --------------------------------- ------------------------------ ------------------------------------ ------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------
  **S-HBsAg**                       *N. tabacum*/transgenic        pBI121/LBA4404                       35S/n.a. \*                           0.01% of TSP                                                                                                                                       Injection, IgA, IgG and IgM antibodies in serum            \[[@B163-ijms-17-01715],[@B175-ijms-17-01715]\]
  *N. tabacum*/transgenic           pGA482/LBA4404                 35S/n.a.                             0.05% of TSP                          n.a.                                                                                                                                               \[[@B176-ijms-17-01715]\]                                  
  *N. tabacum*/transgenic           pBI121/EHA105                  *UBQ3*/ER                            20 ng/g FW                            n.a.                                                                                                                                               \[[@B172-ijms-17-01715]\]                                  
  *N. tabacum*/transgenic           pKHBSBAR/EHA105                35S/n.a.                             10 µg/g FW                            Injection, IgG antibodies in serum (maximum 765 mIU/mL)                                                                                            \[[@B177-ijms-17-01715],[@B178-ijms-17-01715]\]            
  *N. tabacum*/transgenic           pE1802,pE1945/LBA4404          (Aocs)~3~AmasPmas/n.a.               0.06% of TSP                          n.a.                                                                                                                                               \[[@B179-ijms-17-01715]\]                                  
  *N. tabacum*/transgenic           pAMPAT-MCS/GV3101              D35S/n.a.                            2--26 ng/g FW                         Oral, IgA, IgG antibodies in serum                                                                                                                 \[[@B26-ijms-17-01715],[@B180-ijms-17-01715]\]             
  *N. tabacum*/transgenic           pBM/LBA4404                    D35S/n.a.                            0.01%--0.05% of TSP                   n.a.                                                                                                                                               \[[@B181-ijms-17-01715]\]                                  
  *N. benthamiana*/transient        pICH11599/GV3101               Act2/ER                              295 µg/g FW                           Injection, IgG antibodies in serum (maximum 830 mIU/mL)                                                                                            \[[@B30-ijms-17-01715]\]                                   
  *N. benthamiana*/transient        pIBT210/LBA4404                35S/n.a.                             0.05% of TSP                          Injection, IgA and IgG antibodies in serum (maximum 346 mIU/mL)                                                                                    \[[@B182-ijms-17-01715]\]                                  
  NT-1 cell/transgenic              pBI121/EHA105                  UBQ3/ER                              2 µg/g FW                             n.a.                                                                                                                                               \[[@B173-ijms-17-01715]\]                                  
  NT-1 cell/transgenic              pBI121/EHA105                  UBQ3/ER                              31 µg/L culture medium                n.a.                                                                                                                                               \[[@B183-ijms-17-01715]\]                                  
  NT-1 cell/transgenic              pHB155/n.a.                    D35S/n.a.                            8 µg/g FW (2 mg/L culture medium)     n.a.                                                                                                                                               \[[@B174-ijms-17-01715]\]                                  
  NT-1 cell/transgenic              pGPTV-KAN/LBA4404              35S/ER                               0.005%--0.023% of TSP                 Injection, IgG antibodies in serum (maximum 4 mIU/mL)                                                                                              \[[@B184-ijms-17-01715]\]                                  
  Potato/transgenic                 pDES20/GV3101                  D35S/n.a.                            1 µg/g FW (tuber)                     n.a.                                                                                                                                               \[[@B164-ijms-17-01715]\]                                  
  Potato/transgenic                 pBI101/LBA4404                 35S/n.a.                             6 µg/g FW (tuber)                     Injection                                                                                                                                          \[[@B185-ijms-17-01715]\]                                  
  Potato/transgenic                 pBI101/LBA4404                 PAT/n.a.                             1.1 µg/g FW (tuber)                   Oral, IgG antibodies in serum (maximum 1680 mIU/mL)                                                                                                \[[@B165-ijms-17-01715]\]                                  
  Potato/transgenic                 pHB114/LBA4404                 35S/n.a.                             11 µg/g FW (tuber)                    Oral, IgG antibodies in serum (maximum 4785 mIU/mL)                                                                                                \[[@B41-ijms-17-01715]\]                                   
  Potato/transgenic                 pBI121/LBA4404                 PAT/n.a.                             0.09% of TSP (tuber)                  Oral, IgG antibodies in serum (maximum 800 mIU/mL)                                                                                                 \[[@B167-ijms-17-01715]\]                                  
  Potato/transgenic                 pHB114/LBA4404                 35S/n.a.                             8.35 µg/g FW (tuber)                  Oral, IgG antibodies in serum (maximum 3300 mIU/mL)                                                                                                \[[@B166-ijms-17-01715]\]                                  
  Potato/transgenic                 pBM/LBA4404                    D35S/n.a.                            0.05% of TSP (tuber)                  Oral, IgG antibodies in serum (maximum 350 mIU/mL)                                                                                                 \[[@B186-ijms-17-01715]\]                                  
  Potato/transgenic                 pBM/LBA4404                    35S/n.a.                             1 µg/g FW (tuber)                     Oral, IgG antibodies in serum (maximum 350 mIU/mL)                                                                                                 \[[@B186-ijms-17-01715]\]                                  
  Lettuce/transgenic                pROK/LBA4404                   35S/n.a.                             5.5 ng/g FW                           n.a.                                                                                                                                               \[[@B187-ijms-17-01715]\]                                  
  Lettuce/transgenic                pGPTV-BAR/EHA105               35S/n.a.                             60 µg/g FW                            Oral, IgA and IgG antibodies in serum (maximum 38 mIU/mL), Oral (PBS-suspended lyophilized tissue), IgG antibodies in serum (maximum 300 mIU/mL)   \[[@B188-ijms-17-01715],[@B189-ijms-17-01715]\]            
  *A. thaliana*/transgenic          pAMPAT-MCS/GV3101              D35S/n.a.                            3--15 ng/g FW                         Oral, IgA, IgG antibodies in serum                                                                                                                 \[[@B26-ijms-17-01715],[@B180-ijms-17-01715]\]             
  Soybean cell/transgenic           pHB155 vector/n.a.             D35S/n.a.                            (74 μg/g FW) 22 mg/L culture medium   n.a.                                                                                                                                               \[[@B174-ijms-17-01715]\]                                  
  Soybean cell/transgenic           pMSI164/EHA105                 UBQ3/ER                              700 ng/g FW                           n.a.                                                                                                                                               \[[@B190-ijms-17-01715]\]                                  
  Banana/transgenic                 pBI121/EHA105                  EFE ER                               38 ng/g FW (leaf)                     n.a.                                                                                                                                               \[[@B191-ijms-17-01715]\]                                  
  Lupin/transgenic                  pROK/C58                       35S/n.a.                             150 ng/g FW (Callus)                  Oral, IgG antibodies in serum (maximum 19 mIU/mL)                                                                                                  \[[@B187-ijms-17-01715]\]                                  
  Lupin/transgenic                  pROK/GV3101, EHA105, LBA4404   35S/n.a.                             2.5--6 µg/g FW (Callus)               n.a.                                                                                                                                               \[[@B192-ijms-17-01715]\]                                  
  Maize/transgenic                  n.a./EHA101                    3xglb1/Cell wall                     0.51% of TSP (seed)                   n.a.                                                                                                                                               \[[@B168-ijms-17-01715]\]                                  
  Maize/transgenic                  n.a./EHA101                    Glob1/Cell wall                      0.46% of TSP (seed)                   Oral (germ, bioencapsulated), IgA and IgG antibodies in serum (maximum 4632 mIU/mL)                                                                \[[@B193-ijms-17-01715]\]                                  
  Maize/transgenic                  n.a./EHA101                    3kbglb1/Cell wall                    0.41% of TSP (seed)                   Oral (germ, wafer feeding), IgA and IgG antibodies in serum                                                                                        \[[@B194-ijms-17-01715]\]                                  
  Maize/transgenic                  n.a./EHA101                    Glob1/Cell wall                      0.46% of TSP (seed)                   Oral (germ, wafer feeding), IgA and IgG antibodies in serum                                                                                        \[[@B195-ijms-17-01715]\]                                  
  Cherry tomatillo/transgenic       pCAMBIA1301/EHA105             35S/n.a.                             10 ng/g FW (fruit)                    Oral, IgG antibodies in serum                                                                                                                      \[[@B196-ijms-17-01715]\]                                  
  Tomato/transient                  pBI121/EHA105                  EFE/ER                               0.5 µg/g DW (leaf)                    n.a.                                                                                                                                               \[[@B169-ijms-17-01715]\]                                  
  Tomato/transgenic                 pBINPLUS-ARS/LBA4404           35S/ER                               n.a.                                  n.a.                                                                                                                                               \[[@B191-ijms-17-01715]\]                                  
  Tomato/transgenic                 pBM/LBA4404                    D35S/n.a.                            0.01%--0.05% of TSP (leaf)            n.a.                                                                                                                                               \[[@B181-ijms-17-01715]\]                                  
  Tomato/transgenic                 pCAMBIA1301/EHA105             35S/n.a.                             n.a.                                  n.a.                                                                                                                                               \[[@B197-ijms-17-01715]\]                                  
  Tomato/transgenic                 pBINPLUS-ARS/LBA4404           35S/n.a.                             0.3 µg/g DW (fruit)                   Oral, IgA and IgG antibodies in serum (maximum 300 mIU/mL)                                                                                         \[[@B193-ijms-17-01715]\]                                  
  Carrot cell/transgenic            pPCV812/n.a.                   MAS/n.a.                             25 ng/g FW                            n.a.                                                                                                                                               \[[@B198-ijms-17-01715]\]                                  
  *Laminaria japonica*/transgenic   pCAT/n.a.                      SV40/n.a.                            0.05%--0.25% of TSP                   n.a.                                                                                                                                               \[[@B199-ijms-17-01715]\]                                  
  Peanut/transgenic                 pCAMBIA1301/EHA105             35S/n.a.                             240 ng/g FW (bud)                     Injection                                                                                                                                          \[[@B200-ijms-17-01715]\]                                  
  **M-HBsAg**                       *N. tabacum*/transgenic        n.a.                                 n.a.                                  10 µg/g FW                                                                                                                                         Injection, IgG antibodies in serum (maximum 1165 mIU/mL)   \[[@B177-ijms-17-01715]\]
  Tobacco/transgenic                pGPTV-BAR/EHA105               35S/n.a.                             12--21 µg/g FW                        n.a.                                                                                                                                               \[[@B201-ijms-17-01715]\]                                  
  *N. benthamiana*/transient        pIBT210/LBA4404                35S/n.a.                             0.04% of TSP                          Injection, IgA and IgG antibodies in serum (maximum 1165 mIU/mL)                                                                                   \[[@B182-ijms-17-01715]\]                                  
  Potato/transgenic                 pBI121/LBA4404                 PAT/n.a.                             0.012% of TSP (tuber)                 Oral, IgG antibodies in serum (maximum 800 mIU/mL), Oral, IgA and IgG antibodies in serum (maximum 558 mIU/mL)                                     \[[@B167-ijms-17-01715],[@B202-ijms-17-01715]\]            
  Lettuce/transgenic                pGPTV-BAR/EHA105               35S/n.a.                             2--23 µg/g FW                         n.a.                                                                                                                                               \[[@B201-ijms-17-01715]\]                                  
  Tomato/transgenic                 pBINPLUS-ARS/LBA4404           35S/n.a.                             0.002% of TSP (fruit)                 n.a.                                                                                                                                               \[[@B203-ijms-17-01715]\]                                  
  Tomato/transgenic                 pBINPLUS-ARS/AGLO              35S/n.a.                             0.003%--0.021% of TSP (fruit)         Oral (freeze-dried material), IgG antibodies in serum                                                                                              \[[@B204-ijms-17-01715],[@B205-ijms-17-01715]\]            
  Carrot/transgenic                 pBINPLUS-ARS/n.a.              35S/ER                               42 ng/g FW (leaf)                     n.a.                                                                                                                                               \[[@B206-ijms-17-01715]\]                                  
  **L-HBsAg**                       Tobacco/transgenic             pGPTV-BAR/EHA105                     35S/n.a.                              4--13 µg/g FW                                                                                                                                      n.a.                                                       \[[@B201-ijms-17-01715]\]
  Lettuce/transgenic                pGPTV-BAR/EHA105               35S/n.a.                             3--20 µg/g FW                         n.a.                                                                                                                                               \[[@B201-ijms-17-01715]\]                                  
  Tomato/transgenic                 pYPX143/LBA4404                2A11/n.a.                            0.5 µg/g FW (Fruit)                   n.a.                                                                                                                                               \[[@B171-ijms-17-01715]\]                                  
  **Hepatitis B core antigen**      *N. tabacum*/transgenic        pBIN19/LBA4404                       E12Ω/n.a.                             24 µg/g FW                                                                                                                                         n.a.                                                       \[[@B207-ijms-17-01715]\]
  *N. tabacum*/transient            pICH11599/GV3101               35S/n.a.                             2.38 mg/g FW                          Injection and Oral, IgA and IgG antibodies in serum                                                                                                \[[@B208-ijms-17-01715]\]                                  
  *N. benthamiana*/transient        pBINPLUS/LBA4404               35S/n.a.                             1 mg/g FW                             n.a.                                                                                                                                               \[[@B209-ijms-17-01715]\]                                  
  *N. benthamiana*/transient        pBY023/LBA4404                 35S/n.a.                             0.18 mg/g FW                          n.a.                                                                                                                                               \[[@B210-ijms-17-01715]\]                                  
  *N. benthamiana*/transient        pEAQ-HT/LBA4404                35S/n.a.                             0.2--1 mg/g FW                        n.a.                                                                                                                                               \[[@B211-ijms-17-01715]\]                                  

\* n.a.: Not available; TSP, total soluble protein; UBQ3, ubiquitin 3; ER, endoplasmic reticulum; FW, fresh weight; PAT, patatin; PBS, phosphate buffered saline; EFE, ethylene-forming enzyme; DW, dry weight.
